Verastem pens KRAS-focused drug licensing deal with Chugai

Verastem pens KRAS-focused drug licensing deal with Chugai

Source: 
Fierce Biotech
snippet: 

Verastem Oncology has signed a pact to license a drug targeting KRAS-mutation positive cancers from Chugai.